| Breast Cancer |
1 |
1 |
| Advanced and Metastatic Breast Cancer |
0 |
0.91 |
| HER2-Positive Breast Cancer |
0 |
0.77 |
| Triple Negative Breast Cancer |
0 |
0.77 |
| Cancer |
0 |
0.68 |
| Breast |
0 |
0.62 |
| Head and Neck Cancer |
0 |
0.61 |
| Biologic Therapy |
0 |
0.55 |
| Metastasis |
0 |
0.54 |
| Antineoplastic Drug |
0 |
0.51 |
| COVID-19 |
0 |
0.43 |
| Brain Metastasis |
0 |
0.23 |
| Receptors |
0 |
0.21 |
| Aromatase Inhibitors |
0 |
0.15 |
| Estrogen |
0 |
0.15 |
| Tumor |
0 |
0.15 |
| Chemotherapy |
0 |
0.12 |
| Brain |
0 |
0.09 |
| Endocrine Therapy |
0 |
0.06 |
| Adjuvant Setting |
0 |
0.03 |
| Blood |
0 |
0.03 |
| Disease Recurrence |
0 |
0.03 |
| Drug Resistance |
0 |
0.03 |
| Face |
0 |
0.03 |
| Gluteal Region |
0 |
0.03 |
| Grant |
0 |
0.03 |
| Humanized Monoclonal Antibody |
0 |
0.03 |
| Immunotherapy |
0 |
0.03 |
| Neoadjuvant Therapy |
0 |
0.03 |
| Pandemic |
0 |
0.03 |
| Preventive Screening |
0 |
0.03 |
| Surgery |
0 |
0.03 |